Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease

Brain and Behavior

Volumn 3, Issue 3, 2013, Pages 249-262

  Passamonti, Luca ^a,b   Salsone, Maria ^b   Toschi, Nicola ^c   Cerasa, Antonio ^a   Giannelli, Marco ^d   Chiriaco, Carmelina ^a   Cascini, Giuseppe Lucio ^b   Fera, Francesco ^b   Quattrone, Aldo ^a,b  

^a CNR   (Italy)

^b Univ degli Magna Graecia Catanzaro   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Cognition; DAT; Dopamine agonist; fMRI; Parkinson's disease; Working memory

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA;

ADULT; ANXIETY; ARTICLE; ATTENTION; BOLD SIGNAL; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DEPTH PERCEPTION; DISEASE DURATION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAM; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERHEMISPHERIC TRANSFER; LANGUAGE ABILITY; LONG TERM MEMORY; MALE; MENTAL TASK; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT TERM MEMORY; STRIATONIGRAL DEGENERATION; SUPERIOR FRONTAL GYRUS; VERBAL MEMORY; WORKING MEMORY;

EID: 84893503867     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.115     Document Type: Article

References (78)

1. Alegret, M., F. Valldeoriola, M. Marti, M. Pilleri, C. Junque, J. Rumia, et al. 2004. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov. Disord. 19:1463-1469.
2. Alexander, G. M., R. J. Schwartzman, J. R. Grothusen, L. Brainard, and S. W. Gordon. 1993. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following l-dopa treatment. Brain Res. 625:276-282.
3. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. American Psychiatric Publisher, Washington, DC.
4. Antonini, A., J. Schwarz, W. H. Oertel, H. F. Beer, U. D. Madeja, and K. L. Leenders. 1994. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of l-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44:1325-1329.
5. Antonini, A., P. Vontobel, M. Psylla, I. Gunther, P. R. Maguire, J. Missimer, et al. 1995. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 52:1183-1190.
6. Arnsten, A. F., and P. S. Goldman-Rakic. 1998. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch. Gen. Psychiatry 55:362-368.
7. Aron, A. R. 2011. From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol. Psychiatry 69:e55-e68.
8. Aron, A. R., and R. A. Poldrack. 2005. The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biol. Psychiatry 57:1285-1292.
9. Aron, A. R., and R. A. Poldrack. 2006. Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus. J. Neurosci. 26:2424-2433.
10. Baier, B., H. O. Karnath, M. Dieterich, F. Birklein, C. Heinze, and N. G. Muller. 2010. Keeping memory clear and stable - the contribution of human basal ganglia and prefrontal cortex to working memory. J. Neurosci. 30:9788-9792.
11. Beck, A. T., and R. Steer. 1987. Depression inventory scoring manual. The Psychological Corporation, New York.
12. Benton, A. L., N. R. Varney, and K. D. Hamsher. 1978. Visuospatial judgment. A clinical test. Arch. Neurol. 35:364-367.
13. Benton, A. L., K. D. Hamsher, and A. B. Sivan. 1994. Multilingual aphasia examination. AJA Associates, Iowa City.
14. du Boisgueheneuc, F., R. Levy, E. Volle, M. Seassau, H. Duffau, S. Kinkingnehun, et al. 2006. Functions of the left superior frontal gyrus in humans: a lesion study. Brain 129:3315-3328.
15. Bowron, A. 2004. Practical considerations in the use of apomorphine injectable. Neurology 62:S32-S36.
16. Brooks, D. J. 2006 Dopaminergic action beyond its effects on motor function: imaging studies. J. Neurol. 253(Suppl. 4):IV8-IV15.
17. Cline, E. J., U. Scheffel, J. W. Boja, W. M. Mitchell, F. I. Carroll, P. Abraham, et al. 1992. In vivo binding of [125I]RTI-55 to dopamine transporters: pharmacology and regional distribution with autoradiography. Synapse 12:37-46.
18. Cools, R. 2006. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30:1-23.
19. Cools, R., A. Miyakawa, M. Sheridan, and M. D'Esposito. 2010. Enhanced frontal function in Parkinson's disease. Brain 133:225-233.
20. Costa, A., A. Peppe, G. Dell'Agnello, G. A. Carlesimo, L. Murri, U. Bonuccelli, et al. 2003. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease. Dement. Geriatr. Cogn. Disord. 15:55-66.
21. Costa, A., A. Peppe, G. Dell'Agnello, C. Caltagirone, and G. A. Carlesimo. 2009. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 47:1374-1381.
22. De Gaspari, D., C. Siri, A. Landi, R. Cilia, A. Bonetti, F. Natuzzi, et al. 2006. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 77:450-453.
23. De Renzi, E., and L. A. Vignolo. 1962. The token test: a sensitive test to detect receptive disturbances in aphasics. Brain 85:665-678.
24. Decamp, E., T. Wade, and J. S. Schneider. 1999. Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys. Brain Res. 847:134-138.
25. Fischl, B. 2012. FreeSurfer. Neuroimage 62:774-781.
26. Friston, K. J. 1997. Testing for anatomically specified regional effects. Hum. Brain Mapp. 5:133-136.
27. Friston, K. J., A. P. Holmes, K. J. Worsley, J.-P. Poline, C. D. Frith, and R. S. J. Frackowiak. 1994. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2:189-210.
28. de la Fuente-Fernandez, R. 2012. Frontostriatal cognitive staging in Parkinson's disease. Parkinsons Dis. 2012:561046.
29. Giannelli, M., N. Toschi, L. Passamonti, M. Mascalchi, S. Diciotti, and C. Tessa. 2012. Diffusion kurtosis and diffusion-tensor MR imaging in Parkinson disease. Radiology. 265:645-646.
30. Guttman, M., and P. Seeman. 1985. l-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum. J. Neural Transm. 64:93-103.
31. Guttman, M., P. Seeman, G. P. Reynolds, P. Riederer, K. Jellinger, and W. W. Tourtellotte. 1986. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann. Neurol. 19:487-492.
32. Hamilton, M. 1959. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:50-55.
33. Helmich, R. C., E. Aarts, F. P. de Lange, B. R. Bloem, and I. Toni. 2009. Increased dependence of action selection on recent motor history in Parkinson's disease. J. Neurosci. 29:6105-6113.
34. Helmich, R. C., M. J. Janssen, W. J. Oyen, B. R. Bloem, and I. Toni. 2011. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann. Neurol. 69:269-281.
35. Hester, R., C. Fassbender, and H. Garavan. 2004. Individual differences in error processing: a review and reanalysis of three event-related fMRI studies using the GO/NOGO task. Cereb. Cortex 14:986-994.
36. Howell, R. D., E. Breivik, and J. B. Wilcox. 2007. Reconsidering formative measurement. Psychol. Methods 12:205-218.
37. Hughes, A. J., S. E. Daniel, L. Kilford, and A. J. Lees. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55:181-184.
38. Hughes, L. E., R. A. Barker, A. M. Owen, and J. B. Rowe. 2010. Parkinson's disease and healthy aging: independent and interacting effects on action selection. Hum. Brain Mapp. 31:1886-1899.
39. Iavarone, A., B. Ronga, L. Pellegrino, E. Lore, S. Vitaliano, F. Galeone, et al. 2004. The Frontal Assessment Battery (FAB): normative data from an Italian sample and performances of patients with Alzheimer's disease and frontotemporal dementia. Funct. Neurol. 19:191-195.
40. Ichise, M., Y. J. Kim, J. R. Ballinger, D. Vines, S. S. Erami, F. Tanaka, et al. 1999. SPECT imaging of pre- and postsynaptic dopaminergic alterations in l-dopa-untreated PD. Neurology 52:1206-1214.
41. Jenkinson, M., P. Bannister, M. Brady, and S. Smith. 2002. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825-841.
42. Kehagia, A. A., R. A. Barker, and T. W. Robbins. 2010. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 9:1200-1213.
43. LaBar, K. S., D. R. Gitelman, T. B. Parrish, and M. Mesulam. 1999. Neuroanatomic overlap of working memory and spatial attention networks: a functional MRI comparison within subjects. Neuroimage 10:695-704.
44. Laruelle, M., E. Wallace, J. P. Seibyl, R. M. Baldwin, Y. Zea-Ponce, S. S. Zoghbi, et al. 1994. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J. Cereb. Blood Flow Metab. 14:982-994.
45. Lewis, S. J., A. Dove, T. W. Robbins, R. A. Barker, and A. M. Owen. 2003. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J. Neurosci. 23:6351-6356.
46. Lewis, S. J., A. Dove, T. W. Robbins, R. A. Barker, and A. M. Owen. 2004. Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur. J. Neurosci. 19:755-760.
47. Lewis, S. J., A. Slabosz, T. W. Robbins, R. A. Barker, and A. M. Owen. 2005. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 43:823-832.
48. LeWitt, P. A. 2004. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 62:S8-S11.
49. Mackay, C., T. Cox, G. Burrows, and T. Lazzerini. 1978. An inventory for the measurement of self-reported stress and arousal. Br. J. Soc. Clin. Psychol. 17:283-284.
50. Mattay, V. S., A. Tessitore, J. H. Callicott, A. Bertolino, T. E. Goldberg, T. N. Chase, et al. 2002. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann. Neurol. 51:156-164.
51. Millan, M. J., L. Maiofiss, D. Cussac, V. Audinot, J. A. Boutin, and A. Newman-Tancredi. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303:791-804.
52. Montoya, A., S. Lal, M. Menear, E. Duplessis, J. Thavundayil, N. Schmitz, et al. 2008. Apomorphine effects on episodic memory in young healthy volunteers. Neuropsychologia 46:292-300.
53. Moustafa, A. A., S. J. Sherman, and M. J. Frank. 2008. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism. Neuropsychologia 46:3144-3156.
54. Nee, D. E., S. Kastner, and J. W. Brown. 2011. Functional heterogeneity of conflict, error, task-switching, and unexpectedness effects within medial prefrontal cortex. Neuroimage 54:528-540.
55. Nelson, H. E. 1976. A modified card sorting test sensitive to frontal lobe defects. Cortex 12:313-324.
56. Nguyen, T. V., A. L. Brownell, Y. C. Iris Chen, E. Livni, J. T. Coyle, B. R. Rosen, et al. 2000. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 36:57-65.
57. Oak, J. N., J. Oldenhof, and H. H. Van Tol. 2000. The dopamine D(4) receptor: one decade of research. Eur. J. Pharmacol. 405:303-327.
58. Oldfield, R. C. 1971. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97-113.
59. Passamonti, L., A. Cerasa, M. Liguori, M. C. Gioia, P. Valentino, R. Nistico, et al. 2009. Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain 132:3380-3391.
60. Passamonti, L., F. Novellino, A. Cerasa, C. Chiriaco, F. Rocca, M. S. Matina, et al. 2011. Altered cortical-cerebellar circuits during verbal working memory in essential tremor. Brain 134:2274-2286.
61. Rey, A. 1958. Memorisation d'une serie de 15 mots en 5 repetitions. Presses Universitaries des France, Paris.
62. Rowe, J. B., L. Hughes, B. C. Ghosh, D. Eckstein, C. H. Williams-Gray, S. Fallon, et al. 2008. Parkinson's disease and dopaminergic therapy - differential effects on movement, reward and cognition. Brain 131:2094-2105.
63. Ruzicka, E., J. Roth, N. Spackova, P. Mecir, and R. Jech. 1994. Apomorphine induced cognitive changes in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57:998-1001.
64. Schellekens, A. F., K. P. Grootens, C. Neef, K. L. Movig, J. K. Buitelaar, B. Ellenbroek, et al. 2010. Effect of apomorphine on cognitive performance and sensorimotor gating in humans. Psychopharmacology 207:559-569.
65. Scherfler, C., and M. Nocker. 2009. Dopamine transporter SPECT: how to remove subjectivity? Mov. Disord. 24(Suppl. 2):S721-S724.
66. Swainson, R., R. D. Rogers, B. J. Sahakian, B. A. Summers, C. E. Polkey, and T. W. Robbins. 2000. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38:596-612.
67. Todd, R. D., J. Carl, S. Harmon, K. L. O'Malley, and J. S. Perlmutter. 1996. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) denervation in baboons. J. Neurosci. 16:7776-7782.
68. Tomlinson, C. L., R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke. 2010. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 25:2649-2653.
69. Tzourio-Mazoyer, N., B. Landeau, D. Papathanassiou, F. Crivello, O. Etard, N. Delcroix, et al. 2002. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289.
70. van Veen, V., and C. S. Carter. 2002. The anterior cingulate as a conflict monitor: fMRI and ERP studies. Physiol. Behav. 77:477-482.
71. Vijayraghavan, S., M. Wang, S. G. Birnbaum, G. V. Williams, and A. F. Arnsten. 2007. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 10:376-384.
72. Wang, X., P. Zhong, and Z. Yan. 2002. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J. Neurosci. 22:9185-9193.
73. Wechsler, D. 1981. Manual for the Wechsler adult intelligence scale-revised. Psychological Corporation, New York.
74. Williams, G. V., and P. S. Goldman-Rakic. 1995. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572-575.
75. Worsley, K. J., S. Marrett, P. Neelin, A. C. Vandal, K. J. Friston, and A. C. Evans. 1996. A unified statistical approach for determining significant signals in images of cerebral activation. Hum. Brain Mapp. 4:58-73.
76. Zhang, Z., A. H. Andersen, M. J. Avison, G. A. Gerhardt, and D. M. Gash. 2000. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res. 852:290-296.
77. Zhang, Z., A. Andersen, R. Grondin, T. Barber, R. Avison, G. Gerhardt, et al. 2001. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage 14:1159-1167.
78. Zhang, Z., A. H. Andersen, Y. Ai, A. Loveland, P. A. Hardy, G. A. Gerhardt, et al. 2006. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage 33:636-643.